ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
ReciBioPharm , the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics , a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors. On average 30 percent of people with haemophilia A and about 5 percent of people with haemophilia B will develop an inhibitor (an antibody) to the treatment they receive to
Teamspective helps companies optimize their organizational structure by visualizing how communications, information, and decisions flow through their employee networks. By applying AI-powered analysis to employee engagement data, the solution allows companies to ensure every employee’s voice is being heard, enabling employee autonomy and more people-centric organizational decisions.HELSINKI, Finland (March 13th, 2024) – Finnish employee engagement startup Teamspective has raised €900,000 in pre-seed funding. The funding round was led by angel investors, including
